Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Qin, Jianjun; Xue, Liyan; Hao, Anlin; Guo, Xiaofeng; Jiang, Tao; Ni, Yunfeng; Liu, Shuoyan; Chen, Yujie; Jiang, Hongjing; Zhang, Chen; Kang, Mingqiang; Lin, Jihong; Li, Hecheng; Li, Chengqiang; Tian, Hui; Li, Lin; Fu, Junke; Zhang, Yong; Ma, Jianqun; Wang, Xiaoyuan; Fu, Maoyong; Yang, Hao; Yang, Zhaoyang; Han, Yongtao; Chen, Longqi; Tan, Lijie; Dai, Tianyang; Liao, Yongde; Zhang, Weiguo; Li, Bin; Chen, Qixun; Guo, Shiping; Qi, Yu; Wei, Li; Li, Zhigang; Tian, Ziqiang; Kang, Xiaozheng; Zhang, Ruixiang; Li, Yong; Wang, Zhen; Chen, Xiankai; Hou, Zhiguo; Zheng, Rongrong; Zhu, Wenqing; He, Jie; Li, Yin

doi:10.1038/s41591-024-03064-w

Public

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Shared by NobleBlocks on Jul 2, 2024 • 12:00 AM UTC

Authors:

Jianjun Qin

Liyan Xue

Anlin Hao

Abstract

Abstract Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the eff...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!